Core Viewpoint - Berry Genomics (000710.SZ) announced the establishment of a joint venture, Henan Yiyuan Tongkang Gene Technology Co., Ltd., in Zhengzhou, Henan Province, focusing on integrated genetic testing services for newborns and children [1] Group 1: Joint Venture Details - The joint venture will be co-funded by Berry Genomics' wholly-owned subsidiary, Berry Health, which will contribute 600,000 yuan (60% ownership), while individual investor Li Wei will contribute 400,000 yuan (40% ownership) [1] - The registered capital of the joint venture is set at 1 million yuan, primarily allocated for venue rental and initial personnel costs [1] Group 2: Business Operations - The joint venture aims to collaborate closely with public medical institutions and clinical medical enterprises in key regions such as Henan to provide genetic disease testing services [1] - Products and related services, including gene sequencing and AI intelligent services, will primarily be procured from Chengdu Berry Health Gene Technology Co., Ltd. and its subsidiaries [1] Group 3: Future Capital Plans - The joint venture plans to increase its registered capital to no less than 50 million yuan, depending on business progress and operational performance [1]

Core Viewpoint - Berry Genomics (000710.SZ) announced the establishment of a joint venture, Henan Yiyuan Tongkang Gene Technology Co., Ltd., with individual investor Li Wei, focusing on integrated genetic testing services for newborns and children in key regions like Henan [1] Group 1: Joint Venture Details - The joint venture will have a registered capital of 1 million yuan, with Berry and Kang contributing 600,000 yuan (60% ownership) and Li Wei contributing 400,000 yuan (40% ownership) [1] - The joint venture aims to collaborate closely with public medical institutions and clinical medical enterprises [1] Group 2: Funding and Operations - Initial funding will be allocated for rent and personnel costs, with products and services, including gene sequencing and AI intelligent services, sourced from Berry and Kang and its subsidiaries [1] - The joint venture plans to increase its registered capital to no less than 50 million yuan based on business progress and expectations [1]

Group 1 - The core point of the article is that Berry Genomics (000710) announced the establishment of a joint venture, Henan Yiyuan Tongkang Gene Technology Co., Ltd., with an investment of 600,000 yuan from its subsidiary Berry Health and a partner, Li Wei [1] - The registered capital of the joint venture is set at 1 million yuan, focusing on integrated testing services for genetic diseases in newborns and children, in collaboration with public medical institutions and clinical medical enterprises in key regions such as Henan [1] - The joint venture plans to increase its operating capital through capital increases based on business progress, with an expected registered capital of no less than 50 million yuan if the future business performance meets expectations [1]

成都市贝瑞和康基因技术股份有限公司 关于子公司对外投资的自愿性披露公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次子公司对外投资设立合资公司，首期注册资本100万元，主要用于场地租金 和初期人员费用，合资公司的产品及其相关服务（包含基因测序和AI智能体服务等）， 主要通过向成都市贝瑞和康基因技术股份有限公司及其下属主体采购获得。 2、合资公司将根据业务进展情况，通过注册资本增资等方式，扩充合资公司经营 资金。如合资公司未来经营情况符合各方预期，预计注册资本不低于5,000万元。 3、投资标的设立尚需注册地市场监督管理部门审批。 一、子公司对外投资概述 证券代码：000710 证券简称：贝瑞基因 公告编号：2025-040 5、经营范围：一般项目：技术服务、技术开发、技术咨询、技术交流、技术转 让、技术推广；计算机系统服务；信息技术咨询服务；软件开发；诊所服务（工商局注 册，市场监督管理局，卫健委）；健康咨询服务（不含诊疗服务）；仪器仪表销售；计 算机软硬件及辅助设备零售；人工智能硬件销售；专业设计服务；第一类医疗器械销 售；化工产品销 ...

Group 1 - The core point of the article is the establishment of a joint venture company, 河南壹元童康基因科技有限公司, by 贝瑞和康 and individual investor 李巍 in Zhengzhou, Henan Province [1] - The registered capital of the joint venture is set at 1 million yuan, with 贝瑞和康 contributing 600,000 yuan for a 60% stake, while 李巍 invests 400,000 yuan for a 40% stake [1] - The joint venture will focus on products and services including gene sequencing and AI intelligent services, primarily sourcing from 贝瑞基因 and its subsidiaries [1] Group 2 - The future capital of the joint venture is expected to reach no less than 50 million yuan if business operations meet expectations [1] - The establishment of the investment target is subject to approval from the local market supervision and administration department [1]

Group 1 - The article highlights the top 20 stocks with significant capital inflow as of August 7, with Lixun Precision leading at 447 million yuan [1] - Other notable stocks include Huasheng Tiancheng with 345 million yuan and Yingfangwei with 322 million yuan, indicating strong investor interest in these companies [1] - The list also features companies like GoerTek, Jishi Media, and Silan Microelectronics, each attracting over 200 million yuan in capital inflow, suggesting a trend in the technology and electronics sectors [1] Group 2 - The total capital inflow for the top 20 stocks amounts to significant sums, reflecting a robust market sentiment and potential investment opportunities [1] - Companies such as BYD and Yunda Holdings, with inflows of 137 million yuan each, indicate a diverse range of sectors attracting investor attention [1] - The data suggests a concentrated interest in technology and innovation-driven companies, which may signal future growth potential in these industries [1]

Core Viewpoint - The medical device sector is experiencing significant growth, driven by strong performance in the medical device ETF and favorable regulatory developments [1][3]. Group 1: Market Performance - The CSI All Share Medical Device Index (H30217) rose by 2.6%, with notable gains from stocks such as Sainuo Medical (688108), Zhonghong Medical (300981), and Lide Man (300289) [1]. - The medical device ETF (159883) increased by 2.67%, reaching a total share of 5.954 billion, making it the largest among comparable funds [1][2]. - In July, the ETF saw a net subscription of 112 million shares, with a total increase of 1.94 billion shares, marking a record high [1]. Group 2: Regulatory Developments - Recent measures from seven regulatory bodies aim to promote the high-quality development of commercial health insurance and the biopharmaceutical industry, enhancing the payment mechanisms for innovative medical devices [3]. - The National Medical Insurance Administration has emphasized support for genuine innovation in medical devices, rejecting superficial or redundant innovations [3]. Group 3: Pricing and Competition - The National Medical Insurance Administration has clarified that procurement will no longer solely focus on the lowest bid, requiring companies to justify their pricing, which may stabilize prices and profit margins in the medical device sector [4]. - The new procurement rules are expected to enhance the competitive advantage of leading companies with strong product performance and brand recognition [4]. Group 4: Key Holdings - As of June 30, 2025, the top ten weighted stocks in the CSI All Share Medical Device Index accounted for 46.92% of the index, with major players including Mindray Medical (300760) and United Imaging Healthcare (688271) [5].

Core Viewpoint - The company, Berry Genomics (000710), focuses on the reproductive health sector, achieving significant commercial effects in the prenatal testing market while the pre-pregnancy and newborn markets are still in the early stages, indicating substantial market potential [1] Group 1 - The company plans to expand its complex genetic testing services into more areas, leveraging artificial intelligence applications and years of experience in third-generation sequencing technology [1] - The company aims to provide more health services directly to the consumer (C-end) by integrating clinical medical data in the future [1] - The recent changes in major shareholder equity do not impact the company's business development [1]

Core Viewpoint - The company is focusing on the reproductive health sector and aims to expand its business despite ongoing financial challenges and significant credit impairment losses [2]. Group 1: Business Focus and Strategy - The company has achieved good commercial effects in the prenatal testing market but recognizes that the pre-pregnancy and newborn markets are still in the early stages, indicating substantial market potential [2]. - The company plans to leverage artificial intelligence and its years of experience in third-generation sequencing technology to offer complex genetic testing services in more areas [2]. - Future plans include providing more health services directly to end consumers (C-end) by integrating clinical medical data [2]. Group 2: Shareholder and Control Issues - The company stated that the recent judicial auction of shares by major shareholders will not affect its business development [2].

Group 1 - The assisted reproductive industry is experiencing a strong upward trend, with companies such as HanShang Group, FuYuan Pharmaceutical, and LiDeMan reaching their daily price limit [1] - Other companies in the sector, including GongTong Pharmaceutical, DaJia WeiKang, SiChuang YiHui, BoTuo Bio, BeiRui Gene, and MaiDi Technology, also saw significant increases in their stock prices [1]